In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution.

ABSTRACT: Iron deficiency anemia is treated by iron supplementation. Increasing evidence has shown that the carbohydrate components in iron infusions can cause hypophosphatemia and subsequent osteomalacia due to excess intact fibroblast growth factor 23 (iFGF23). We here undertook an in-depth characterization of 13 patients with iron infusion-induced osteomalacia (IIIO). Patients were characterized (monocentric institutional practice) by means of laboratory, bone density, HR-pQCT, and virtual osteoid volume estimation. We additionally report a patient who was treated with burosumab because iron infusions had to be continued despite osteomalacia. All 13 patients received ferric carboxymaltose (FCM) infusions and presented with low phosphate levels. Stopping the FCM infusions and supportive treatment

SUBMITTER: von Brackel FN 

PROVIDER: S-EPMC11631080 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature